Erratum to Dimethyl Fumarate (Tecfidera): A New Oral Agent for Multiple Sclerosis (Ann Pharmacother, (2013), 47, 12 (1697-1702), 10.1177/1060028013509232);Dimethyl Fumarate (Tecfidera): A New Oral Agent for Multiple Sclerosis

Annals of Pharmacotherapy

Volumn 47, Issue 12, 2013, Pages 1697-1702

  Venci, Jineane V ^a   Gandhi, Mona A ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ST JOHN FISHER COLLEGE   (United States)

Author keywords

ambulatory care; clinical pharmacy; drug information; evidence based practice; multiple sclerosis; neurology

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; DIARRHEA; DISTRIBUTION VOLUME; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EXPANDED DISABILITY STATUS SCALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

AMBULATORY CARE; CLINICAL PHARMACY; DRUG INFORMATION; EVIDENCE-BASED PRACTICE; MULTIPLE SCLEROSIS; NEUROLOGY;

ADMINISTRATION, ORAL; DRUG INTERACTIONS; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84891676458     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014529923     Document Type: Erratum

References (28)

1. LongoDL. Harrison's principles of internal medicine. In: Multiple Sclerosis and Other Demyelinating Diseases. 18th ed.New York, NY: McGraw-Hill; 2012:chap 380. http://www.accessmedicine.com/content.aspx?aID=9147780. Accessed September 3, 2013.
2. Alonso A,Hernan MA.Temporal trends in the incidence of multiple sclerosis: a systematic review.Neurology. 2008;71:129-135.
3. Center for Drug Evaluation and Research. Medical review: dimethyl fumarate. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000MedR.pdf. Accessed August 1, 2013.
4. Tecfidera (dimethyl fumarate) [package insert]. Cambridge MA: Biogen Idec Inc; 2013:.
5. Scannevin RH,Chollate S,Jung MYet al.Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.J Pharmacol Exp. 2012;341:274-284.
6. Lin SX,Lisi L,Dello Russo Cet al.The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1.ASN Neuro. 2011;3 (pii): e00055.
7. Gold R,Kappos L,Arnold DLet al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.N Engl J Med. 2012;367:1098-1107.
8. Fox RJ,Miller DH,Phillips JTet al.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.N Engl J Med. 2012;367:1087-1097.
9. Polman CH,Reingold SC,Edan Get al.Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.Ann Neurol. 2005;58:840-846.
10. Kurtzke JF.Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS).Neurology. 1983;33:1444-1452.
11. Center for Drug Evaluation and Research. Summary review: dimethyl fumarate. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000SumR.pdf. Accessed August 1, 2013.
12. Hoefnagel JJ,Thio HB,Willemze R,Bouwes Bavinck JN.Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.Br J Dermtol. 2003;149:363-369.
13. Sweetser MT,Dawson KT,Bozic C.Manufacturer's response to case reports of PML.N Engl J Med. 2013;368:1659-1661.
14. Klawiter EC,Cross AH,Naismith RT.The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%?.Neurology. 2009;73:984-990.
15. Polman CH,O'Connor PW,Havrdova Eet al.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med. 2006;354:899-910.
16. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.Neurology. 1993;43:655-661.
17. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.Lancet. 1998;352:1498-1504.
18. Johnson KP,Brooks BR,Cohen JAet al.Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.Neurology. 1995;45:1268-1276.
19. Jacobs LD,Cookfair DL,Rudick RAet al.Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).Ann Neurol. 1996;39:285-294.
20. Kappos L,Radue EW,O'Connor Pet al.A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med. 2010;362:387-401.
21. O'Connor P,Wolinsky JS,Confavreux Cet al.Randomized trial of oral teriflunomide for relapsing multiple sclerosis.N Engl J Med. 2011;365:1293-1303.
22. US Food and Drug Administration. FDA Drug Safety Communication: Safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod). http://www.fda.gov/Drugs/DrugSafety/ucm284240.htm#data. Accessed August 1, 2013.
23. US Food and Drug Administration. FDA drug safety communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm. Accessed August 8, 2013.
24. Gilenya (fingolimod) [package insert]. East Hanover, NJ: Novartis; 2013:.
25. Cambridge, MA: Genzyme; 2012:.
26. Ormerod AD,Mrowietz U.Fumaric acid esters, their place in the treatment of psoriasis.Br J Dermtol. 2004;150:630-632.
27. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=dimethyl+fumarate&Search=Search. Accessed Aug 1, 2013.
28. RED BOOK Drug References. Truven Health Analytics. http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micromedex_clinical_evidence_sols/med_safety_solutions/red_book/. Accessed August 1, 2013.